Conference Agenda
November 17, 2020
SESSION 1: WORLD-WIDE DADA2 COHORTS
TELL US SOMETHING NEW!
All times listed are in Eastern Standard Time (Washington D.C. time)
17
November
2020
7:00 a.m. - 7:40 a.m.
Sign into Virtual Conference
Check Internet | Check Audio & Video Connection
17
November
2020
7:40 a.m. - 8:10 a.m.
Welcome/Introductions/Agenda Overview
Chip Chambers, M.D. - Founder & President DADA2 Foundation
Dan Kastner, M.D., Ph.D. - Scientific Director NHGRI, National Institutes of Health, USA
17
November
2020
8:10 a.m. - 8:25 a.m.
India DADA2 Cohort - Inaugural DADA2 Conference Lecture
Aman Sharma, M.D. – Postgraduate Institute of Medical Education & Research, Chandigarh, India
17
November
2020
8:25 a.m. - 8:40 a.m.
Belgium DADA2 Cohort
Isabelle Meyts, M.D., Ph.D. – University Hospitals Gasthuisberg, Leuven, Belgium
17
November
2020
8:40 a.m. - 8:55 a.m.
Canada DADA2 Cohort
Kelly Brown, Ph.D. – BC Children’s Hospital Research Institute, Vancouver, BC, Canada
17
November
2020
8:55 a.m. - 9:10 a.m.
China DADA2 Cohort
Qing Zhou, M.D. – Zhejiang University, Hangzhou, China
17
November
2020
9:10 a.m. - 9:25 a.m.
England DADA2 Cohort
Samantha Cooray, M.D., Ph.D. – UCL Institute of Child Health, London, England
17
November
2020
9:25 a.m. - 9:40 a.m.
Finland DADA2 Cohort
Janna Saarela, M.D., Ph.D. - Institute for Molecular Medicine, Helsinki, Finland
17
November
2020
9:40 a.m. - 9:55 a.m.
France DADA2 Cohort
Alexandre Belot, M.D., Ph.D. - Hospices Civils de Lyon, Lyon, France
Sophie Georgin-Lavialle, M.D., Ph.D. - Pierre and Marie Curie University, Paris, France
17
November
2020
9:55 a.m. - 10:05 a.m.
BREAK
17
November
2020
10:05 a.m. - 10:20 a.m.
Germany DADA2 Cohort
Bodo Grimbacher, M.D. – Center for Chronic Immunodeficiency, Freiburg, Germany
17
November
2020
10:20 a.m. - 10:35 a.m.
Israel DADA2 Cohort
Yackov Berkun, M.D. - Hadassah Hebrew University Medical Center, Jerusalem, Israel
17
November
2020
10:35 a.m. - 10:50 a.m.
Italy DADA2 Cohort
Marco Gattorno, M.D. - Giannina Gaslini Institute, Genoa, Italy
17
November
2020
10:50 a.m. - 11:05 a.m.
Japan DADA2 Cohort
Kazushi Izawa, M.D., Ph.D. – Kyoto University Hospital, Kyoto, Japan
17
November
2020
11:05 a.m. - 11:20 a.m.
Netherlands DADA2 Cohort
Joris Van Montfrans, M.D., Ph.D. – University Medical Center Utrecht, Utrecht, The Netherlands
17
November
2020
11:20 a.m. - 11:35 a.m.
NIH | USA DADA2 Cohort
Karyl Barron, M.D. – NIAID/NIH, Bethesda Maryland, USA
17
November
2020
11:35 a.m. - 11:50 a.m.
South America DADA2 Cohort
Gustavo Santo, M.D. – Hospitais da Universidade, Coimbra, Portugal
17
November
2020
11:50 a.m. - 12:05 p.m.
Spain DADA2 Cohort
Juan Ignacio Aróstegui, M.D. – Hospital Clinic-Biomedical Diagnostic Center, Barcelona, Spain
17
November
2020
12:05 p.m. - 12:20 p.m.
Turkey DADA2 Cohort
Seza Ozen, M.D. - Hacettepe University, Dept of Pediatrics, Ankara, Turkey
17
November
2020
12:20 p.m. - 12:30 p.m.
Q&A via Chat
Selected questions submitted through chat will be answered live by presenters, with remaining questions answered via written communication after the conference.
November 18, 2020
SESSION 2: NEW INSIGHTS IN DADA2
THINGS YOU NEED TO KNOW
All times listed are in Eastern Standard Time (Washington D.C. time)
18
November
2020
7:00 a.m. - 7:40 a.m.
Sign into Virtual Conference
Check Internet | Check Audio & Video Connection
18
November
2020
7:40 a.m. - 8:10 a.m.
Welcome/Introductions/Agenda Overview
Chip Chambers, M.D. - Founder & President DADA2 Foundation
Dan Kastner, M.D., Ph.D. - Scientific Director NHGRI, National Institutes of Health, USA
18
November
2020
8:10 - 8:30 a.m.
Neurological Phenotype of DADA2 – The Neurologists' Perspective
Timothy Bernard, M.D. University of Colorado School of Medicine, Denver, Colorado USA
18
November
2020
8:30 a.m. - 8:50 a.m.
Dermatological Phenotype of DADA2 – The Dermatologists' Perspective
Edward Cowen, M.D. – Dermatology Branch | NCI/NIH, Bethesda, Maryland USA
18
November
2020
8:50 a.m. - 9:10 a.m.
Non-Invasive Vascular Testing & Cardiac Phenotype of DADA2 – The Cardiologists' Perspective
Alessandra Brofferio, M.D. – NHLBI/NIH, Bethesda, Maryland USA
18
November
2020
9:10 a.m. - 9:30 a.m.
Immunodeficiency Phenotype of DADA2 – The Immunologists' Perspective
Troy Torgerson, M.D., Ph.D. – Allen Institute for Immunology, Seattle, Washington USA
18
November
2020
9:30 a.m. - 9:50 a.m.
Efficacy of TNF-Inhibitors in Treating DADA2
Amanda Ombrello, M.D. – NHGRI/NIH, Bethesda, Maryland USA
18
November
2020
9:50 a.m. - 10:00 a.m.
BREAK
18
November
2020
10:00 a.m. - 10:20 a.m.
Genotype & Functional Correlates of Disease Phenotype in DADA2
Pui Lee, M.D., Ph.D. – Harvard Medical School, Boston, Massachusetts USA
18
November
2020
10:20 a.m. - 10:40 a.m.
Analysis of DADA2 Pathogenesis Based on Single Cell RNA Sequencing of Monocytes
Alice Wu, M.D., Ph.D. – NHLBI/NIH, Bethesda, Maryland USA
18
November
2020
10:40 a.m. - 11:00 a.m.
How Not to Miss the Diagnosis of DADA2
Ivona Aksentijevich, M.D. – NHGRI/NIH, Bethesda, Maryland USA
18
November
2020
11:00 a.m. - 11:20 a.m.
The Diagnosis of DADA2 in 30 mins at the Point of Care – Is it Possible?
Carson Chen, Ph.D. - iXensor, Taipei City, Taiwan
18
November
2020
11:20 a.m. - 11:40 p.m.
Can the Prevalence of DADA2 be Estimated?
Anne O’Donnell Luria, M.D., Ph.D. – Broad Institute at MIT, Cambridge, Massachusetts USA
Samantha Baxter, MS, LGC – Broad Institute at MIT, Cambridge, Massachusetts USA
18
November
2020
11:40 a.m. - 12:30 p.m.
Q&A via Chat
Selected questions submitted through chat will be answered live by presenters, with remaining questions answered via written communication after the conference.
November 19, 2020
SESSION 3: FIRE SIDE CHATS
TOPICS THAT NEED A CONSENSUS
All times listed are in Eastern Standard Time (Washington D.C. time)
19
November
2020
7:00 a.m. - 7:40 a.m.
Sign into Virtual Conference
Check Internet | Check Audio & Video Connection
19
November
2020
7:40 a.m. - 8:00 a.m.
Welcome/Introductions/Agenda Overview
Chip Chambers, M.D. - Founder & President DADA2 Foundation
Dan Kastner, M.D., Ph.D. - Scientific Director NHGRI, National Institutes of Health USA
19
November
2020
8:00 a.m. - 8:20 a.m.
What to Do About the Asymptomatic DADA2 Patient?
Taryn Youngstein, M.D. - Imperial College Healthcare NHS Trust, London, England
19
November
2020
8:20 a.m. - 8:40 a.m.
Interpreting Variants of Unknown Significance in Patients with Sign/Symptoms of DADA2
Pui Lee, M.D., Ph.D. – Harvard Medical School, Boston, Massachusetts USA
19
November
2020
8:40 a.m. - 10:10 a.m.
What is the Function of ADA2? – Can We Design a Research Agenda to Answer that Question?
Sonia Sharma, Ph.D. – La Jolla Institute for Immunology, La Jolla, California USA
Ole Kristian Greiner-Tollersrud, Ph.D. – Institute of Medical Biology University of Tromsø, Norway
Michele Proeitti, M.D. Ph.D. – Center for Chronic Immunodeficiency, Freiburg, Germany
Peter Grayson, M.D. – NIAMS/NIH, Bethesda, Maryland USA
Kazushi Izawa, M.D., Ph.D. – Kyoto University Hospital, Kyoto, Japan
Dan Kastner, M.D., Ph.D. – Moderator | Scientific Director, NHGRI/NIH, Bethesda, Maryland USA
19
November
2020
10:10 a.m. - 11:00 a.m.
What is the Best Approach to Hematopoietic Stem Cell Transplant for DADA2?
Jennifer Kanakry, M.D. – NCI/NIH, Bethesda, Maryland USA
Isabelle Meyts, M.D., Ph.D. – University Hospitals Gasthuisberg, Leuven, Belgium
Mrinal Patnaik, MBBS – Moderator | Mayo Clinic, Rochester, Minnesota, USA
19
November
2020
11:00 a.m. - 12:10 p.m.
Can DADA2 be Cured by Gene Therapy & Gene Editing?
Despina Eleftheriou, MBBS, MRCPCH, Ph.D. - UCL Institute of Child Health, London, England
Alessandra Mortellaro, Ph.D. - San Raffaele Telethon Institute for Gene Therapy, Milan, Italy
Rachel Diamant, MSc Eng – EMENDO Biotherapeutics, New York, New York, USA
Harry Malech, M.D. – Moderator | NIAID/NIH, Bethesda, Maryland USA
19
November
2020
12:10 p.m. - 12:30 p.m.
Conclusion 3rd International Conference on the Deficiency of Adenosine Deaminase 2